10% Owner ADAR1 Capital Buys $118K of InMed Stock Over Three Days
INM has more than doubled off its 52-week low of $0.575.
Summary
10% owner ADAR1 Capital Management bought $118K of InMed stock over three days, increasing its stake to 892,101 shares amid the company's going concern warning and pending reverse merger.
Key Events · Ownership and Investor Activity · INM
-
10% Owner Buys $118K
ADAR1 Capital Management, managed by Daniel Schneeberger, purchased 91,101 shares for $118,076.02 across three transactions from September 14-16 at prices ranging $1.26-$1.31.
-
Stake Rises to 892,101 Shares
Post-transaction holdings total 892,101 shares, held indirectly through private investment funds managed by ADAR1 Capital Management.
-
Purchase Amid Going Concern
The buying follows InMed's September 9 FY2026 10-K, which disclosed a going concern qualification and only $2.2M in cash runway into September 2026.
-
Merger Context
The purchase occurs while InMed's all-stock reverse merger with Mentari Therapeutics is pending; existing InMed shareholders are projected to own just 1.01% of the combined company.
Analysis · INM · Life Sciences
ADAR1 Capital Management, a 10% owner managed by Daniel Schneeberger, bought 91,101 shares for $118,076 across three days at $1.26-$1.31. The purchase comes just days after InMed's FY2026 10-K disclosed a going concern qualification and only $2.2M in cash runway into September 2026, with the pending Mentari reverse merger as the primary path forward. A large holder adding to its position at this juncture is a notable vote of confidence in the merger's completion, though the dollar amount is modest relative to the company's distress.
How filings like this one have moved
In the 30 days to Sep 16, 2026, 29.6% of the 1716 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.32%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, INM was trading at $1.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7M. The 52-week trading range was $0.58 to $2.50. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.